Lv38
310 积分 2024-12-03 加入
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
13天前
已完结
Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma
14天前
已完结
Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma
14天前
已关闭
Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma
21天前
已完结
Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia
21天前
已完结
Pretherapy metabolic tumor volume associates with response to CD30 CAR T cells in Hodgkin lymphoma
21天前
已关闭
Abstract 5222: Biomarkers associated with complete metabolic response (CMR) to nivolumab and brentuximab vedotin (nivo + BV) for the treatment of children, adolescents, and young adults (CAYA) with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) in the CheckMate 744 study
27天前
已关闭
PHASE 2 KEYNOTE‐667: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH CLASSICAL HODGKIN LYMPHOMA (CHL) WITH SLOW EARLY RESPONSE TO FRONT‐LINE CHEMOTHERAPY
27天前
已完结
LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation
1个月前
已完结
Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment
1个月前
已完结
皖公网安备34019202002308
